Effect  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
CYP1A2  ||| S:10 E:17 ||| CD
polymorphism  ||| S:17 E:30 ||| NN
on  ||| S:30 E:33 ||| IN
the  ||| S:33 E:37 ||| DT
pharmacokinetics  ||| S:37 E:54 ||| NN
of  ||| S:54 E:57 ||| IN
agomelatine  ||| S:57 E:69 ||| NN
in  ||| S:69 E:72 ||| IN
Chinese  ||| S:72 E:80 ||| JJ
healthy  ||| S:80 E:88 ||| JJ
male  ||| S:88 E:93 ||| JJ
volunteers  ||| S:93 E:104 ||| JJ
Agomelatine  ||| S:104 E:116 ||| NNP
is  ||| S:116 E:119 ||| VBZ
a  ||| S:119 E:121 ||| DT
melatonin  ||| S:121 E:131 ||| NN
( ||| S:131 E:132 ||| -LRB-
MT ||| S:132 E:134 ||| NNP
)  ||| S:134 E:136 ||| -RRB-
analogue  ||| S:136 E:145 ||| NN
with  ||| S:145 E:150 ||| IN
agonistic  ||| S:150 E:160 ||| JJ
properties  ||| S:160 E:171 ||| NNS
and  ||| S:171 E:175 ||| CC
has  ||| S:175 E:179 ||| VBZ
been  ||| S:179 E:184 ||| VBN
proven  ||| S:184 E:191 ||| VBN
to  ||| S:191 E:194 ||| TO
be  ||| S:194 E:197 ||| VB
effective  ||| S:197 E:207 ||| JJ
for  ||| S:207 E:211 ||| IN
various  ||| S:211 E:219 ||| JJ
types  ||| S:219 E:225 ||| NNS
of  ||| S:225 E:228 ||| IN
depressive  ||| S:228 E:239 ||| JJ
symptoms ||| S:239 E:247 ||| NNS
.  ||| S:247 E:249 ||| .
Following  ||| S:249 E:259 ||| VBG
oral  ||| S:259 E:264 ||| JJ
administration ||| S:264 E:278 ||| NN
,  ||| S:278 E:280 ||| ,
agomelatine  ||| S:280 E:292 ||| NN
is  ||| S:292 E:295 ||| VBZ
primarily  ||| S:295 E:305 ||| RB
metabolized  ||| S:305 E:317 ||| VBN
by  ||| S:317 E:320 ||| IN
the  ||| S:320 E:324 ||| DT
hepatic  ||| S:324 E:332 ||| FW
cytochrome  ||| S:332 E:343 ||| FW
P450  ||| S:343 E:348 ||| FW
isoenzyme  ||| S:348 E:358 ||| FW
CYP1A2 ||| S:358 E:364 ||| FW
.  ||| S:364 E:366 ||| .
The  ||| S:366 E:370 ||| DT
purpose  ||| S:370 E:378 ||| NN
of  ||| S:378 E:381 ||| IN
this  ||| S:381 E:386 ||| DT
study  ||| S:386 E:392 ||| NN
was  ||| S:392 E:396 ||| VBD
to  ||| S:396 E:399 ||| TO
assess  ||| S:399 E:406 ||| VB
the  ||| S:406 E:410 ||| DT
influence  ||| S:410 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
CYP1A2  ||| S:423 E:430 ||| CD
single  ||| S:430 E:437 ||| JJ
nucleotide  ||| S:437 E:448 ||| JJ
polymorphisms  ||| S:448 E:462 ||| NNS
( ||| S:462 E:463 ||| -LRB-
SNPs ||| S:463 E:467 ||| NNP
,  ||| S:467 E:469 ||| ,
rs762551 ||| S:469 E:477 ||| NNP
,  ||| S:477 E:479 ||| ,
rs2069514 ||| S:479 E:488 ||| NNP
,  ||| S:488 E:490 ||| ,
rs2472304 ||| S:490 E:499 ||| NNP
,  ||| S:499 E:501 ||| ,
rs2470890 ||| S:501 E:510 ||| CD
)  ||| S:510 E:512 ||| -RRB-
on  ||| S:512 E:515 ||| IN
agomelatine  ||| S:515 E:527 ||| JJ
pharmacokinetics  ||| S:527 E:544 ||| NN
in  ||| S:544 E:547 ||| IN
the  ||| S:547 E:551 ||| DT
Chinese  ||| S:551 E:559 ||| JJ
population ||| S:559 E:569 ||| NN
.  ||| S:569 E:571 ||| .
Seventy-two  ||| S:571 E:583 ||| JJ
healthy  ||| S:583 E:591 ||| JJ
Chinese  ||| S:591 E:599 ||| JJ
male  ||| S:599 E:604 ||| JJ
volunteers  ||| S:604 E:615 ||| NNS
enrolled  ||| S:615 E:624 ||| VBD
in  ||| S:624 E:627 ||| IN
the  ||| S:627 E:631 ||| DT
study  ||| S:631 E:637 ||| NN
received  ||| S:637 E:646 ||| VBD
an  ||| S:646 E:649 ||| DT
oral  ||| S:649 E:654 ||| JJ
dose  ||| S:654 E:659 ||| NN
of  ||| S:659 E:662 ||| IN
25 mg  ||| S:662 E:668 ||| CD
of  ||| S:668 E:671 ||| IN
agomelatine  ||| S:671 E:683 ||| NN
after  ||| S:683 E:689 ||| IN
providing  ||| S:689 E:699 ||| VBG
written  ||| S:699 E:707 ||| VBN
informed  ||| S:707 E:716 ||| VBN
consent ||| S:716 E:723 ||| NN
.  ||| S:723 E:725 ||| .
CYP1A2  ||| S:725 E:732 ||| NNP
SNPs  ||| S:732 E:737 ||| NNP
were  ||| S:737 E:742 ||| VBD
genotyped  ||| S:742 E:752 ||| VBN
by  ||| S:752 E:755 ||| IN
polymerase  ||| S:755 E:766 ||| JJ
chain  ||| S:766 E:772 ||| NN
reaction-restriction  ||| S:772 E:793 ||| JJ
fragment  ||| S:793 E:802 ||| NN
length  ||| S:802 E:809 ||| NN
polymorphism  ||| S:809 E:822 ||| NNS
( ||| S:822 E:823 ||| -LRB-
PCR-RFLP ||| S:823 E:831 ||| NNP
) ||| S:831 E:832 ||| -RRB-
.  ||| S:832 E:834 ||| .
Agomelatine  ||| S:834 E:846 ||| JJ
plasma  ||| S:846 E:853 ||| NN
concentrations  ||| S:853 E:868 ||| NNS
were  ||| S:868 E:873 ||| VBD
determined  ||| S:873 E:884 ||| VBN
by  ||| S:884 E:887 ||| IN
high  ||| S:887 E:892 ||| JJ
performance  ||| S:892 E:904 ||| NN
liquid  ||| S:904 E:911 ||| JJ
chromatography-tandem  ||| S:911 E:933 ||| JJ
mass  ||| S:933 E:938 ||| NN
spectrometry ||| S:938 E:950 ||| NN
,  ||| S:950 E:952 ||| ,
and  ||| S:952 E:956 ||| CC
the  ||| S:956 E:960 ||| DT
pharmacokinetics  ||| S:960 E:977 ||| JJ
analyses  ||| S:977 E:986 ||| NNS
were  ||| S:986 E:991 ||| VBD
evaluated  ||| S:991 E:1001 ||| VBN
by  ||| S:1001 E:1004 ||| IN
nonparametric  ||| S:1004 E:1018 ||| JJ
methods ||| S:1018 E:1025 ||| NNS
.  ||| S:1025 E:1027 ||| .
After  ||| S:1027 E:1033 ||| IN
a  ||| S:1033 E:1035 ||| DT
single  ||| S:1035 E:1042 ||| JJ
oral  ||| S:1042 E:1047 ||| JJ
dose  ||| S:1047 E:1052 ||| NN
of  ||| S:1052 E:1055 ||| IN
25 mg  ||| S:1055 E:1061 ||| CD
agomelatine ||| S:1061 E:1072 ||| NN
,  ||| S:1072 E:1074 ||| ,
no  ||| S:1074 E:1077 ||| DT
significant  ||| S:1077 E:1089 ||| JJ
differences  ||| S:1089 E:1101 ||| NNS
existed  ||| S:1101 E:1109 ||| VBD
in  ||| S:1109 E:1112 ||| IN
agomelatine  ||| S:1112 E:1124 ||| JJ
pharmacokinetics  ||| S:1124 E:1141 ||| NN
between  ||| S:1141 E:1149 ||| IN
the  ||| S:1149 E:1153 ||| DT
rs2069514  ||| S:1153 E:1163 ||| FW
GG  ||| S:1163 E:1166 ||| FW
homozygotes  ||| S:1166 E:1178 ||| FW
( ||| S:1178 E:1179 ||| -LRB-
n = 35 ||| S:1179 E:1185 ||| NNP
)  ||| S:1185 E:1187 ||| -RRB-
and  ||| S:1187 E:1191 ||| CC
the  ||| S:1191 E:1195 ||| DT
rs2069514  ||| S:1195 E:1205 ||| NNP
AG  ||| S:1205 E:1208 ||| NNP
allele  ||| S:1208 E:1215 ||| NNS
( ||| S:1215 E:1216 ||| -LRB-
n = 35 ||| S:1216 E:1222 ||| NNP
)  ||| S:1222 E:1224 ||| -RRB-
in  ||| S:1224 E:1227 ||| IN
all  ||| S:1227 E:1231 ||| DT
subjects ||| S:1231 E:1239 ||| NNS
.  ||| S:1239 E:1241 ||| .
The  ||| S:1241 E:1245 ||| DT
mean  ||| S:1245 E:1250 ||| JJ
agomelatine  ||| S:1250 E:1262 ||| JJ
AUC0-7  ||| S:1262 E:1269 ||| NN
,  ||| S:1269 E:1271 ||| ,
AUC0-∞  ||| S:1271 E:1278 ||| NNP
and  ||| S:1278 E:1282 ||| CC
Cmax  ||| S:1282 E:1287 ||| NNP
for  ||| S:1287 E:1291 ||| IN
the  ||| S:1291 E:1295 ||| DT
rs762551  ||| S:1295 E:1304 ||| FW
CC  ||| S:1304 E:1307 ||| FW
homozygotes  ||| S:1307 E:1319 ||| FW
( ||| S:1319 E:1320 ||| -LRB-
n = 9 ||| S:1320 E:1325 ||| NNP
) ||| S:1325 E:1326 ||| -RRB-
,  ||| S:1326 E:1328 ||| ,
rs2470890  ||| S:1328 E:1338 ||| FW
CC  ||| S:1338 E:1341 ||| FW
homozygotes  ||| S:1341 E:1353 ||| FW
( ||| S:1353 E:1354 ||| -LRB-
n = 54 ||| S:1354 E:1360 ||| NNP
)  ||| S:1360 E:1362 ||| -RRB-
and  ||| S:1362 E:1366 ||| CC
rs2472304  ||| S:1366 E:1376 ||| NNP
GG  ||| S:1376 E:1379 ||| NNP
homozygotes  ||| S:1379 E:1391 ||| NNS
( ||| S:1391 E:1392 ||| -LRB-
n = 51 ||| S:1392 E:1398 ||| NNP
)  ||| S:1398 E:1400 ||| -RRB-
were  ||| S:1400 E:1405 ||| VBD
much  ||| S:1405 E:1410 ||| RB
higher  ||| S:1410 E:1417 ||| JJR
than  ||| S:1417 E:1422 ||| IN
the  ||| S:1422 E:1426 ||| DT
rs762551  ||| S:1426 E:1435 ||| JJ
AA  ||| S:1435 E:1438 ||| NN
allele  ||| S:1438 E:1445 ||| NNS
( ||| S:1445 E:1446 ||| -LRB-
n = 31 ||| S:1446 E:1452 ||| NNP
) ||| S:1452 E:1453 ||| -RRB-
,  ||| S:1453 E:1455 ||| ,
rs2470890  ||| S:1455 E:1465 ||| FW
CT  ||| S:1465 E:1468 ||| FW
allele  ||| S:1468 E:1475 ||| FW
( ||| S:1475 E:1476 ||| -LRB-
n = 17 ||| S:1476 E:1482 ||| NNP
)  ||| S:1482 E:1484 ||| -RRB-
and  ||| S:1484 E:1488 ||| CC
rs2472304  ||| S:1488 E:1498 ||| NNP
AG  ||| S:1498 E:1501 ||| NNP
allele  ||| S:1501 E:1508 ||| NNS
( ||| S:1508 E:1509 ||| -LRB-
n = 20 ||| S:1509 E:1515 ||| NNP
)  ||| S:1515 E:1517 ||| -RRB-
respectively  ||| S:1517 E:1530 ||| RB
( ||| S:1530 E:1531 ||| -LRB-
P   ||| S:1531 E:1533 ||| NNP
< ||| S:1533 E:1534 ||| SYM
 0.05 ||| S:1534 E:1539 ||| NNP
) ||| S:1539 E:1540 ||| -RRB-
.  ||| S:1540 E:1542 ||| .
The  ||| S:1542 E:1546 ||| DT
rs762551  ||| S:1546 E:1555 ||| NNP
A ||| S:1555 E:1556 ||| NNP
,  ||| S:1556 E:1558 ||| ,
rs2470890  ||| S:1558 E:1568 ||| CD
T  ||| S:1568 E:1570 ||| NN
and  ||| S:1570 E:1574 ||| CC
rs2472304  ||| S:1574 E:1584 ||| CD
A  ||| S:1584 E:1586 ||| DT
genotype  ||| S:1586 E:1595 ||| NN
presented  ||| S:1595 E:1605 ||| VBD
a  ||| S:1605 E:1607 ||| DT
significantly  ||| S:1607 E:1621 ||| RB
lower  ||| S:1621 E:1627 ||| JJR
level  ||| S:1627 E:1633 ||| NN
of  ||| S:1633 E:1636 ||| IN
agomelatine  ||| S:1636 E:1648 ||| JJ
exposure  ||| S:1648 E:1657 ||| NN
( ||| S:1657 E:1658 ||| -LRB-
AUC ||| S:1658 E:1661 ||| NNP
,  ||| S:1661 E:1663 ||| ,
Cmax  ||| S:1663 E:1668 ||| NNP
)  ||| S:1668 E:1670 ||| -RRB-
compared  ||| S:1670 E:1679 ||| VBN
with  ||| S:1679 E:1684 ||| IN
the  ||| S:1684 E:1688 ||| DT
rs762551  ||| S:1688 E:1697 ||| NNP
C ||| S:1697 E:1698 ||| NNP
,  ||| S:1698 E:1700 ||| ,
rs2470890  ||| S:1700 E:1710 ||| NNP
C  ||| S:1710 E:1712 ||| NNP
and  ||| S:1712 E:1716 ||| CC
rs2472304  ||| S:1716 E:1726 ||| NNP
G  ||| S:1726 E:1728 ||| NNP
genotype  ||| S:1728 E:1737 ||| NN
in  ||| S:1737 E:1740 ||| IN
Chinese  ||| S:1740 E:1748 ||| JJ
healthy  ||| S:1748 E:1756 ||| JJ
subjects ||| S:1756 E:1764 ||| NNS
.  ||| S:1764 E:1766 ||| .
It  ||| S:1766 E:1769 ||| PRP
suggested  ||| S:1769 E:1779 ||| VBD
that  ||| S:1779 E:1784 ||| IN
the  ||| S:1784 E:1788 ||| DT
rs762551 ||| S:1788 E:1796 ||| NNP
,  ||| S:1796 E:1798 ||| ,
rs2470890  ||| S:1798 E:1808 ||| NNP
and  ||| S:1808 E:1812 ||| CC
rs2472304  ||| S:1812 E:1822 ||| CD
genetic  ||| S:1822 E:1830 ||| JJ
polymorphism  ||| S:1830 E:1843 ||| NN
might  ||| S:1843 E:1849 ||| MD
be  ||| S:1849 E:1852 ||| VB
associated  ||| S:1852 E:1863 ||| VBN
with  ||| S:1863 E:1868 ||| IN
the  ||| S:1868 E:1872 ||| DT
marked  ||| S:1872 E:1879 ||| JJ
interindividual  ||| S:1879 E:1895 ||| JJ
variability  ||| S:1895 E:1907 ||| NN
of  ||| S:1907 E:1910 ||| IN
agomelatine ||| S:1910 E:1921 ||| NN
,  ||| S:1921 E:1923 ||| ,
and  ||| S:1923 E:1927 ||| CC
the  ||| S:1927 E:1931 ||| DT
pharmacokinetic  ||| S:1931 E:1947 ||| JJ
profile  ||| S:1947 E:1955 ||| NN
of  ||| S:1955 E:1958 ||| IN
agomelatine  ||| S:1958 E:1970 ||| NNS
may  ||| S:1970 E:1974 ||| MD
be  ||| S:1974 E:1977 ||| VB
different  ||| S:1977 E:1987 ||| JJ
in  ||| S:1987 E:1990 ||| IN
different  ||| S:1990 E:2000 ||| JJ
races ||| S:2000 E:2005 ||| NNS
.  ||| S:2005 E:2007 ||| .
